Nyxoah Archives | Be Korea-savvy
Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Mont-Saint-Guibert, Belgium. Aug. 18 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17th Annual Wells Fargo Securities Healthcare Conference, which takes place September 7-9, 2022, [...]

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

Mont-Saint-Guibert, Belgium, Aug. 8 (Korea Bizwire)– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2022.   Second Quarter 2022 Financial and Operating Highlights [...]

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

Mont-Saint-Guibert, Belgium, Aug. 2 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has entered into a distribution agreement with Acurable SL, a venture-backed medical device company developing wearable [...]

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

Mont-Saint-Guibert, Belgium, July 27 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Canaccord Genuity 42nd Annual Growth Conference, which will take place in Boston, Massachusetts, [...]

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

Mont-Saint-Guibert, Belgium, July 19 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half of 2022 on Monday, August [...]

Nyxoah Announces CE Mark Approval for Genio® 2.1

Nyxoah Announces CE Mark Approval for Genio® 2.1

Mont-Saint-Guibert, Belgium, July 18 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the DEKRA Notified Body has approved the use of Nyxoah’s next generation Genio® 2.1 system for patients in [...]

Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients

Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients

Mont-Saint-Guibert, Belgium, July 11 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) to enable Nyxoah to [...]

Information on the Total Number of Voting Rights and Shares

Information on the Total Number of Voting Rights and Shares

Mont-Saint-Guibert (Belgium), June 30 (Korea Bizwire) – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new shares.  Share capital: EUR 4,438,351.16   Total number of securities carrying voting rights: 25,836,279 (all ordinary shares)   Total number of voting rights (= denominator): 25,836,279 (all [...]

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

Mont-Saint-Guibert, Belgium, June 7 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), is proud to announce that it is part of the newly-formed Euronext Tech Leaders initiative, which is composed of 100+ innovative [...]

FDA Approves Genio® 2.1 for Use in DREAM U.S. IDE Pivotal Study

FDA Approves Genio® 2.1 for Use in DREAM U.S. IDE Pivotal Study

Mont-Saint-Guibert, Belgium, June 1 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Nyxoah’s next generation Genio® 2.1 system [...]